| Antibodies to costimulatory receptor 4-1BB enhance anti-tumor immunity via T regulatory cell depletion and promotion of CD8 T cell effector function SL Buchan, L Dou, M Remer, SG Booth, SN Dunn, C Lai, M Semmrich, ... Immunity 49 (5), 958-970. e7, 2018 | 138 | 2018 |
| Antibody distance from the cell membrane regulates antibody effector mechanisms KLS Cleary, HT Chan, S James, MJ Glennie, MS Cragg The Journal of Immunology 198 (10), 3999-4011, 2017 | 119 | 2017 |
| Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma CK Rushton, SE Arthur, M Alcaide, M Cheung, A Jiang, KM Coyle, ... Blood advances 4 (13), 2886-2898, 2020 | 85 | 2020 |
| Development of a T-cell receptor mimic antibody against wild-type p53 for cancer immunotherapy D Li, C Bentley, A Anderson, S Wiblin, KLS Cleary, S Koustoulidou, ... Cancer research 77 (10), 2699-2711, 2017 | 31 | 2017 |
| Regulation of monoclonal antibody immunotherapy by FcγRIIB RJ Stopforth, KLS Cleary, MS Cragg Journal of clinical immunology 36, 88-94, 2016 | 23 | 2016 |
| Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’tumors M Semmrich, JB Marchand, L Fend, M Rehn, C Remy, P Holmkvist, ... Journal for Immunotherapy of Cancer 10 (1), 2022 | 22 | 2022 |
| CD20 and its antibodies: past, present, and future RJ Oldham, KLS Cleary, MS Cragg Onco Therapeutics 5 (1-2), 2014 | 15 | 2014 |
| HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy K Hussain, R Liu, RCG Smith, KTJ Müller, M Ghorbani, S Macari, ... Journal of Experimental & Clinical Cancer Research 41 (1), 131, 2022 | 13 | 2022 |
| Targeting TNFR2 for cancer immunotherapy: Ligand blocking depletors versus receptor agonists L Mårtensson, K Cleary, M Semmrich, M Kovacek, P Holmkvist, ... Cancer Res 80 (16_Supplement), 936, 2020 | 7 | 2020 |
| 757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab KS Rohrberg, Z Papai, A Carneiro, I Lang, J Yachnin, S Lim, L Ny, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | 2 | 2023 |
| Recurrent patterns of clonal evolution in relapsed-refractory DLBCL following treatment with R-CHOP C Rushton, SE Arthur, M Alcaide, M Cheung, N Thomas, LK Hilton, ... Blood 134, 921, 2019 | 2 | 2019 |
| A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo HD Collier-Bain, A Emery, AJ Causer, FF Brown, R Oliver, D Dutton, ... Brain, Behavior, and Immunity 118, 468-479, 2024 | 1 | 2024 |
| 1368 Preclinical development of an agonistic anti-TNFR2 antibody (BI-1910) for cancer immunotherapy L Martensson, P Holmkvist, M Kovacek, C Svensson, M Bodén, K Cleary, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | 1 | 2023 |
| Immunological methods to study monoclonal antibody activity in chronic lymphocytic Leukaemia MJ Carter, LN Dahal, KLS Cleary, MJE Marshall, RR French, SA Beers, ... Chronic Lymphocytic Leukemia: Methods and Protocols, 173-184, 2019 | 1 | 2019 |
| 19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab. KS Rohrberg, Z Papai, RL Eefsen, J Yachnin, A Carneiro, SH Lim, ... Journal of Clinical Oncology 42 (16_suppl), 2641-2641, 2024 | | 2024 |
| A Single Bout of Exercise Enhances the Efficacy of Rituximab Against Autologous Chronic Lymphocytic Leukaemia B Cells Ex Vivo By Transiently Increasing Natural Killer Cell … HD Collier-Bain, A Emery, AJ Causer, FF Brown, R Oliver, D Dutton, ... Blood 142, 1179, 2023 | | 2023 |
| Abstract IA42: Detecting and quantifying mutations associated with treatment resistance in aggressive lymphomas using ctDNA N Thomas, LK Hilton, N Michaud, K Bushell, R Rys, M Jain, L Shepherd, ... Blood Cancer Discovery 1 (3_Supplement), IA42-IA42, 2020 | | 2020 |
| Impact of target antigen properties on antibody effector mechanisms K Cleary University of Southampton, 2015 | | 2015 |
| Understanding antibody immunotherapy: the distance between antibody binding and the cell membrane impacts the depletion mechanisms engaged KLS Cleary, CHT Chan, MJ Glennie, MS Cragg IMMUNOLOGY 143, 126-127, 2014 | | 2014 |
